Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer

被引：3

作者：

Clark, Joseph I. ^{[1
,2
]}

Eisner, Robert M. ^{[1
]}

Hofmeister, Craig ^{[3
]}

Norton, John ^{[1
]}

Thomas, Sachdev ^{[1
]}

Choudhury, Abdul ^{[2
]}

Petruzzelli, Guy ^{[4
]}

Lathers, Deanne ^{[5
]}

Young, M. Rita I. ^{[5
,6
]}

Lau, Ann ^{[1
]}

Emami, Bahman ^{[7
]}

机构：

[1] Loyola Univ, Med Ctr, Dept Med, Div Hematol Oncol,Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA

[2] Jr Hines VA Hosp, Med Serv, Hines, IL USA

[3] Ohio State Univ, Dept Hematol, Columbus, OH 43210 USA

[4] Rush Univ, Med Ctr, Dept Otolaryngol, Chicago, IL 60612 USA

[5] Ralph H Johnson VA Med Ctr, Dept Otolaryngol, Res Serv, Charleston, SC USA

[6] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA

[7] Loyola Univ, Med Ctr, Dept Radiat Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2009年 / 32卷 / 04期

关键词：

phase I; radiochemotherapy; docetaxel; high risk; head and neck cancer; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; ACTIVE-DRUG; CHEMOTHERAPY; FLUOROURACIL; CISPLATIN; INFUSION; TRIAL;

D O I：

10.1097/COC.0b013e31818da9c7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: This phase I study was designed to determine the maximum tolerated dose (MTD) and preliminary efficacy of docetaxel with concurrent radiotherapy (RT), in high-risk squamous cell carcinoma of the head and neck. Patients and Methods: Eligible patients had resected squamous cell carcinoma of the head and neck, histologically involved lymph nodes, and/or extranodal disease, and/or involved surgical margins and performance status 0 to 1. Treatment included weekly docetaxel with concurrent RT in a dose-finding study; a subsequent small cohort of patients was treated using the MTD of docetaxel. Results: Twenty patients were enrolled. Planned accrual was 25, but the study was closed prematurely because of slow accrual. The MTD was 15 mg/m(2). Dose-limiting toxicity was oral stomatitis. Therapy was well tolerated. Five patients experienced locoregional relapse at a median follow-up of 32 months. Conclusion: Docetaxel with concurrent RT has acceptable toxicity. This approach warrants further investigation in a phase II trial.

引用

页码：396 / 400

页数：5

共 50 条

[31] Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer
Witek, Matthew E.
Woody, Neil M.
Musunuru, Hima B.
Hill, Patrick M.
Yadav, Poonam
Burr, Adam R.
Ko, Huaising C.
Ross, Richard B.
Kimple, Randall J.
Harari, Paul M.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (02): : 317 - 324
[32] Phase 1/2 Study of Preoperative Docetaxel and Mitoxantrone for High-Risk Prostate Cancer
Garzotto, Mark
Higano, Celestia S.
O'Brien, Catherine
Rademacher, Brooks L. S.
Janeba, Nicole
Fazli, Ladan
Lange, Paul H.
Lieberman, Stephen
Beer, Tomasz M.
CANCER, 2010, 116 (07) : 1699 - 1708
[33] Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer
Argiris, A.
Karamouzis, M. V.
Smith, R.
Kotsakis, A.
Gibson, M. K.
Lai, S. Y.
Kim, S.
Branstetter, B. F.
Shuai, Y.
Romkes, M.
Wang, L.
Grandis, J. R.
Ferris, R. L.
Johnson, J. T.
Heron, D. E.
ANNALS OF ONCOLOGY, 2011, 22 (11) : 2482 - 2488
[34] Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis
Christiane Matuschek
Jan Haussmann
Edwin Bölke
Stephan Gripp
Patrick J. Schuler
Bálint Tamaskovics
Peter Arne Gerber
Freddy-Joel Djiepmo-Njanang
Kai Kammers
Christian Plettenberg
Bahar Anooshahr
Klaus Orth
Wilfried Budach
Radiation Oncology, 13
[35] Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan
Goshi Nishimura
Osamu Shiono
Daisuke Sano
Kenichiro Yabuki
Yasuhiro Arai
Yoshihiro Chiba
Teruhiko Tanabe
Nobuhiko Oridate
Cancer Chemotherapy and Pharmacology, 2017, 80 : 203 - 207
[36] A Phase II Study of Docetaxel, Cisplatin and 5-Fluorouracil (TPF) In Patients with Locally Advanced Head and Neck Carcinomas
Ansari, M.
Omidvari, S.
Mosalaei, A.
Ahmadloo, N.
Mosleh-Shirazi, M. A.
Mohammadianpanah, M.
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2011, 13 (03) : 187 - 191
[37] Phase II Feasibility Trial of Adjuvant Chemoradiotherapy with 3-weekly Cisplatin for Japanese Patients with Post-operative High-risk Squamous Cell Carcinoma of the Head and Neck
Kiyota, Naomi
Tahara, Makoto
Okano, Susumu
Kawashima, Mitsuhiko
Matsuura, Kazuto
Onozawa, Yuske
Nibu, Kenichi
Hayashi, Ryuichi
Yoshimura, Kenichi
Ohtsu, Atsushi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (10) : 927 - 933
[38] Nomogram to predict risk of early mortality following definitive or adjuvant radiation and systemic therapy for head and neck cancer
Raab, Gabriel
Yu, Yao
Sherman, Eric
Wong, Richard
Mell, Loren K.
Lee, Nancy Y.
Zakeri, Kaveh
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 45
[39] A Phase I Study of Concurrent Chemoradiotherapy Using Oral S-1 for Head and Neck Cancer
Fujimoto, Yasushi
Kato, Satoshi
Itoh, Yoshiyuki
Naganawa, Shinji
Nakashima, Tsutomu
ANTICANCER RESEARCH, 2014, 34 (1A) : 209 - 213
[40] Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy
Mencoboni, M.
Grillo-Ruggieri, F.
Salami, A.
Scasso, F.
Rebella, L.
Grimaldi, A.
Dellepiane, M.
Moratti, G.
Bruzzone, A.
Spigno, F.
Ghio, R.
Figliomeni, M.
EUROPEAN JOURNAL OF CANCER CARE, 2011, 20 (04) : 503 - 507

← 1 2 3 4 5 →